drugset
drugset / Trial / NCT02652936

A Pharmacokinetics Study of AF-130 in Healthy Subjects

NCT02652936 ↗

Phase 1 Completed 80 enrolled Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 2-part, single centre, single (Part 1) and multiple (Part 2) dose escalation study in healthy male subjects.

Timeline

Start
2015-10
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AF-130 Unknown 50 mg Oral

Indications

No indication recorded.